BioCentury
ARTICLE | Finance

Nailing down NLRP3

Why investors backed $37M series A for inflammasome play NodThera

June 29, 2018 1:22 PM UTC

The next-generation chemistry behind its NLRP3 inhibitors enabled inflammasome play NodThera Ltd. to close a £28 million ($37 million) series A round led by Sofinnova Partners and 5AM Ventures.

F-Prime Capital Partners and founding investor Epidarex Capital also joined the round, which was announced on June 25...